Melphalan Amarox (Melphalan Hydrochloride)

Melphalan hydrochloride alkylates guanine bases in DNA, forming cross‑links that block DNA replication and transcription. This damage triggers programmed cell death, preferentially affecting rapidly proliferating tumour cells while sparing most normal tissues.

The dose of Melphalan Amarox is individualized by the prescribing oncologist based on the specific cancer type, disease stage, patient weight, renal function and treatment protocol. Only a qualified healthcare professional should determine the appropriate regimen.

Melphalan Amarox is classified as contraindicated in pregnancy unless the potential benefit justifies the risk to the fetus. It is also not recommended during breastfeeding because it can be excreted in milk and may harm the infant.

To request Melphalan Amarox, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

Melphalan Amarox shares the DNA‑cross‑linking mechanism of other alkylating agents such as cyclophosphamide, but it is often preferred for certain haematologic and solid tumours due to its potency and established efficacy in multiple myeloma and ovarian cancer. Toxicity profiles are similar, with myelosuppression being a common concern.

Melphalan Amarox should be stored at 2‑8 °C in a refrigerator, protected from light and moisture. The product must not be frozen or shaken, and it should remain in its original packaging until ready for reconstitution and administration.

Melphalan Amarox is supplied as a sterile injectable solution and is administered by a qualified healthcare professional via intravenous infusion or intra‑arterial injection, according to the prescribed treatment schedule and infusion rate.

The most serious risks include severe myelosuppression leading to infection or bleeding, secondary leukaemia, renal toxicity, and rare pulmonary complications. Patients should be closely monitored for blood counts, kidney function and any signs of infection throughout therapy.

Melphalan Amarox is contraindicated in patients with known hypersensitivity to melphalan or any component of the formulation, in pregnant women unless absolutely necessary, and in individuals with severe renal impairment where dose adjustment is not feasible. Caution is also advised for patients receiving live vaccines.